The address of each Reporting Person, other than Nachum Shamir, is 1000 Westbank Dr, Ste #2A, Austin, TX 78746. George Walter Loewenbaum, Elizabeth S. Loewenbaum, Lilian S. Loewenbaum, Patrick Chalmers and Reginald J. Hargrove are citizens of the United States and their current occupations are individual private investors. Nachum Shamir is a dual citizen of Israel and the United States and his occupation is a private investor. His address is 7900 Escala Dr, Austin TX 78735.

Refer (b) above

During the last five years, none of the Reporting Persons nor any general partner or trustee of the Reporting Entities (a) has been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors), or (b) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.

Refer (d) above

Refer (b) above

The information concerning the ownership of Ordinary Shares of the Reporting Persons set forth on the cover pages hereto is expressly incorporated by reference herein.

On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with the Issuer for the purchase of 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 Ordinary Shares (the "Series A Warrants"), and Series B Warrants to purchase 3,529,412 Ordinary Shares (the "Series B Warrants" and, together with the Series A Warrants, the "Warrants"). The transaction was completed on July 6, 2026. The Series A Warrants have an exercise price of $0.34 per share and are exercisable as of July 29, 2026, the date of shareholder approval (the "Shareholder Approval Date"). The Series A Warrants expire on July 16, 2028. The Series B Warrants have an exercise price of $0.34 per share and are exercisable as of the Shareholder Approval Date. The Series B Warrants expire on July 16, 2031. The Loewenbaum 1992 Trust is only permitted to exercise the Warrants up to a beneficial ownership limitation of 24.99% (the "Beneficial Ownership Limitation"). The acquisitions of Ordinary Shares and Warrants by the Reporting Persons was for investment purposes. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price of and other market conditions relating to the Ordinary Shares or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations, and other factors deemed relevant, may form a plan or proposal to take any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, in which case the Reporting Persons will file an amendment to this Schedule 13D. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.

The information concerning the ownership of the Ordinary Shares of the Reporting Persons set forth on the cover pages hereto is expressly incorporated by reference herein. To the best knowledge of the Reporting Persons, as of July 29, 2026, there were 18,908,207 Ordinary Shares outstanding, as set forth in the Form F-3 filed by the Issuer with the SEC on July 9, 2026. The calculations of percentages in this Schedule 13D are based on 22,628,318 Ordinary Shares outstanding as of July 29, 2026, which is based on the 18,908,207 Ordinary Shares as set forth by the Issuer, plus 3,720,111 Ordinary Shares, which is the approximate maximum number of Ordinary Shares obtainable upon exercise of the Warrants up to the Beneficial Ownership Limitation. Collectively, the Reporting Persons beneficially own in the aggregate 7,473,536 Ordinary Shares, representing 33.0% of the total outstanding Ordinary Shares (including approximately 3,720,111 Ordinary Shares that may be issued to the Reporting Persons within 60 days upon the exercise of options and warrants up to the Beneficial Ownership Limitation).

The information concerning the ownership of Ordinary Shares of the Reporting Persons set forth on the cover pages hereto is expressly incorporated by reference herein.

Not applicable.

Except as listed in Item 5(a), to the best knowledge of the Reporting Persons, no person other than the Reporting Persons has the right to receive, or the power to direct the receipt of dividends from, or the power to direct the receipt of proceeds of the sale of the shares of Common Stock beneficially owned by the Reporting Persons.

Not applicable.

The Reporting Persons have entered into a Joint Filing Agreement, dated October 20, 2025, a copy of which is attached hereto as Exhibit 2 to this Schedule 13D and is incorporated herein by reference.

1. Joint Filing Agreement dated January 28, 2025 (incorporated by reference to Exhibit A to the Schedule 13G/A filed by the Reporting Persons on January 28, 2025). 2. Joint Filing Agreement dated October 20, 2025 (incorporated by reference to Exhibit 2 to the Schedule 13D/A filed by the Reporting Persons on October 20, 2025).